Skip to main content Accessibility help

Occlutech® muscular ventricular septal defect device: the first reported human use

  • Gareth J. Morgan (a1)


Percutaneous closure of muscular ventricular septal defects has been well described and has not attracted the same controversy or scrutiny as perimembranous defect closure. Therefore, the development of specifically designed devices has been limited. We report the first use of the Occlutech® muscular ventricular septal defect device. Does its design add any significant benefit?


Corresponding author

Correspondence to: Dr G. J. Morgan, MB, BaO, BCh, MPhil, MRCPCH, Department of Congenital Cardiology, Guys and St Thomas’ NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, United Kingdom. Tel:+4 420 7188 9617; Fax:+4 420 7188 4556; E-mail:


Hide All
1. Cantinotti, M, Assanta, N, Murzi, B, Lopez, L. Controversies in the definition and management of insignificant left-to-right shunts. Heart 2014; 100: 200205.
2. Carminatti, M, Buttera, G, Chessa, M, et al. Transcatheter closure of congenital ventricular septal defects: results of the European Registry. Eur Heart J 2007; 28: 23612368.
3. Haas, N, Happel, CM, Soetemann, DB, et al. Optimal septal alignment of the Figulla ® Flex occluder to the atrial septum in patients with secundum atrial septal defects. Eurointervention 2016; 11: 11531160.
4. Dankowski, R, Baszko, A, Sutherland, M, et al. 3D heart model printing for preparation of percutaneous structural interventions: description of the technology and case report. Kardiol Pol 2014; 72: 546551.
5. Kenny, D, Morgan, G, Bajwa, A, et al. Evolution of transcatheter closure of perimembranous ventricular septal defects in a single centre. Catheter Cardiovasc Interv 2009; 73: 568575.
6. Pedra, CA, Pedra, SF, Costa, RN, et al. Mid-term outcomes after percutaneous closure of the secundum atrial septal defect with the Figulla-Occlutech ® device. J Interv Cardiol 2016; 29: 208215.
7. Zartner, P, Christians, C, Stelter, JC, Hraska, V, Schneider, MB. Transvascular closure of single and multiple muscular ventricular septal defects in neonates and infants <20kg. Catheter Cardiovasc Interv 2014; 83: 564570.
8. Shibbani, K, Kenny, D, McElhnney, D, Hijazi, ZM, Moran, T. Identifying gaps in technology for congenital interventions: analysis of a needs survey from Congenital Interventional Cardiologists. Pediatr Cardiol 2016; 37: 925931.


Occlutech® muscular ventricular septal defect device: the first reported human use

  • Gareth J. Morgan (a1)


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed